Discovery - University of Dundee - Online Publications

Library & Learning Centre

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

Research output: Contribution to journalArticle

View graph of relations

Authors

  • John G. F. Cleland
  • John R. Teerlink
  • Roxy Senior
  • Evgeny M. Nifontov
  • John J. V. McMurray
  • Vitaly A. Tsyrlin
  • Barry H. Greenberg
  • Jamil Mayet
  • Darrel P. Francis
  • Tamaz Shaburishvili
  • Mark Monaghan
  • Mitchell Saltzberg
  • Ludwig Neyses
  • Scott M. Wasserman
  • Jacqueline H. Lee
  • Khalil G. Saikali
  • Cyril P. Clarke
  • Jonathan H. Goldman
  • Andrew A. Wolff
  • Fady I. Malik

Research units

Info

Original languageEnglish
Pages676-683
Number of pages8
JournalLancet
Journal publication date20 Aug 2011
Volume378
Issue9792
DOIs
StatePublished

Abstract

Background Many patients with heart failure remain symptomatic and have a poor prognosis despite existing treatments. Decreases in myocardial contractility and shortening of ventricular systole are characteristic of systolic heart failure and might be improved by a new therapeutic class, cardiac myosin activators. We report the first study of the cardiac myosin activator, omecamtiv mecarbil, in patients with systolic heart failure.

Methods We undertook a double-blind, placebo-controlled, crossover, dose-ranging, phase 2 trial investigating the effects of omecamtiv mecarbil (formerly CK-1827452), given intravenously for 2, 24, or 72 h to patients with stable heart failure and left ventricular systolic dysfunction receiving guideline-indicated treatment. Clinical assessment (including vital signs, echocardiograms, and electrocardiographs) and testing of plasma drug concentrations took place during and after completion of each infusion. The primary aim was to assess safety and tolerability of omecamtiv mecarbil. This study is registered at ClinicalTrials.gov, NCT00624442.

Findings 45 patients received 151 infusions of active drug or placebo. Placebo-corrected, concentration-dependent increases in left ventricular ejection time (up to an 80 ms increase from baseline) and stroke volume (up to 9.7 mL) were recorded, associated with a small reduction in heart rate (up to 2.7 beats per min; p<0.0001 for all three measures). Higher plasma concentrations were also associated with reductions in end-systolic (decrease of 15 mL at >500 ng/mL, p=0.0026) and end-diastolic volumes (16 mL, p=0.0096) that might have been more pronounced with increased duration of infusion. Cardiac ischaemia emerged at high plasma concentrations (two patients, plasma concentrations roughly 1750 ng/mL and 1350 ng/mL). For patients tolerant of all study drug infusions, no consistent pattern of adverse events with either dose or duration emerged.

Interpretation Omecamtiv mecarbil improved cardiac function in patients with heart failure caused by left ventricular dysfunction and could be the first in class of a new therapeutic agent.

Documents

Library & Learning Centre

Contact | Accessibility | Policy